Palbociclib blocks neutrophilic PI3K activity to alleviate psoriasiform dermatitis.

Po-Jen ChenHsin-Hui TsengYi-Hsuan WangShu-Yen FangShun-Hua ChenChun-Hong ChenSheng-Chieh TsaiYu-Chia ChangYung-Fong TsaiTsong-Long Hwang

Published in: British journal of pharmacology (2023)

This is the first study to demonstrate that palbociclib could potentially be used to treat neutrophil-associated psoriasiform dermatitis through the targeting of neutrophilic PI3K activity. Our findings prompt further research to explore the potential of palbociclib and PI3K in psoriasis and other inflammatory diseases.

Keyphrases

metastatic breast cancer
atopic dermatitis
oxidative stress
cancer therapy
risk assessment
drug delivery